# Centre Jean Perrin: Phase 2 study closed enrollment, 66 enrolled (Glioblastoma)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Centre Jean Perrin |
| Sponsor type | Academic and hospital |
| Study | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma |
| NCT ID | NCT04881032 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Glioblastoma |
| Intervention types | drug, radiation |
| Target enrollment | 66 |
| Site countries | France |
| Posted | 2021-05-11 |
| Planned start | 2022-03-07 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04881032). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.